Accumulation of azithromycin and roxithromycin in tracheal epithelial fetal cell lines expressing wild type or mutated Cystic Fibrosis Transmembrane Conductance Regulator Protein (CFTR)

Journal of Chemotherapy

Volumn 17, Issue 4, 2005, Pages 385-392

  Labro, M T ^a,c   Babin Chevaye, C ^a   Mergey, M ^b  

^a Section of Radiology   (France)

^b INSERM   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Azithromycin; Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator (CFTR); Macrolide; Roxithromycin

Indexed keywords

AZITHROMYCIN; MACROLIDE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; ROXITHROMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; VERAPAMIL;

ARTICLE; CELL ADHESION; CELL COUNT; CELL LINE; CELL VOLUME; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG UPTAKE; EPITHELIUM CELL; GENE MUTATION; HUMAN; HUMAN CELL; INCUBATION TIME; ISOTOPE LABELING; PHAGOCYTE; PROTEIN EXPRESSION; TRACHEA MUCOSA; WILD TYPE;

EID: 24644514449     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.4.385     Document Type: Article

References (42)

1. Quinton PM. Physiological basis of cystic fibrosis: a historical perspective. Physiol Rev 1999; 79 Suppl: S3-S22.
2. Derelle J. [Anti-inflammatory therapy in cystic fibrosis][Article in French] Arch Pediatr 2003; 10 Suppl 2: 370s-375s.
3. Martinez FJ, Simon RH. Clinical implications of macrolide therapy in chronic sinopulmonary diseases. Curr Pharm Des 2004; 10(25): 3095-110.
4. Garey KW, Alwani A, Danziger LH, Rubinstein I. Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases. Chest 2003; 123(1): 261-5.
5. Hansen CR, Pressler T, Koch C, Hoiby N. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros 2005; 4: 35-40.
6. Siddiqui J. Immunomodulatory effects of macrolides: implications for practicing clinicians. Am J Med 2004; 117 Suppl 9A: 26S-29S.
7. Labro MT, Abdelghaffar H. Immunomodulation by macrolide antibiotics. J Chemother 2001; 13(1): 3-8.
8. Labro MT. Cellular and molecular effects of macrolides Current Pharmaceut Design 2004; 10, (25): 3067-3080.
9. Labro MT. Cellular accumulation of macrolide antibiotics. Intracellular bioactivity.. In: Schönfeld W, Kirst H (Eds.). Macrolide Antibiotics. Birkhäuser Verlag AG. 2002: 37-52.
10. Vazifeh D, Abdelghaffar H, Labro MT. Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin. Antimicrob Agents Chemother 1997; 41: 2099-2107.
11. Vazifeh D, Preira A, Bryskier A, Labro MT. Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils. Antimicrob Agents Chemother 1998; 42: 1944-1951.
12. Labro MT, Abdelghaffar H, Babin-Chevaye C. Interaction between the new ketolide, ABT-773 (cethromycin) and human polymorphonuclear neutrophils and the phagocytic cell line PLB-985 in vitro. Antimicrob Agents Chemother 2004; 48: 1096-1104.
13. Abdelghaffar H, Soukri A, Babin-Chevaye C, Labro MT. Interaction of macrolides and ketolides with the phagocytic cell line PLB-985. J Chemother 2003; 15 (4): 350-356.
14. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 1989; 58: 137-171.
15. Fardel O, Lecureur V, Guillouzo A. The P-glycoprotein multidrug transporter. Gen Pharmac 1996; 27: 1283-1291.
16. Wakasugi H, Yano I, Ito T, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998; 64: 123-128.
17. Arceci RJ, Stieglitz K, Bierer BE. Immunosuppressant FK506 and rapamycin function as reversal agents of the multidrug-resistance phenotype. Blood 1992; 80: 1528-1536.
18. Crosta L, Candiloro V, Meli M, Tolomeo M, Rausa L, Dusonchet. Lacidipine and josamycin: two new multidrug resistance modulators. Anticancer Res 1994; 14: 2685-2690.
19. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077-6080.
20. Lemnanouar M, Chastre E, Paul A, et al. Oncogene-mediated propagation of tracheal epithelial cells from two cystic fibrosis fetuses with different mutations. Characterization of CFT-1 and CFT-2 cells in culture. Eur J Clin Invest 1993; 23(3): 151-160.
21. Mergey M, Lemnaouar M, Veissiere D, et al. CFTR gene transfer corrects defective glycoconjugate secretion in human CF epithelial tracheal cells. Am J Physiol 1995; 269 (13): L855-L864.
22. Carlier MB, Scorneaux B, Zenebergh A, Desnottes JF, Tulkens PM. Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages. J Antimicrob Chemother 1990; 26 (Suppl. B): 27-39.
23. Rubin BK, Henke MO. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 2004; 125 (2 Suppl): 70S-78S.
24. Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004; 54(1): 21-28.
25. Wolter JM, Seeney SL, McCormack JG. Macrolides in cystic fibrosis: is there a role? Am J Respir Med 2002; 1(4): 235-241.
26. Southern KW, Barker PM. Azithromycin for cystic fibrosis. Eur Respir J 2004; 24(5): 834-838.
27. Saiman L. The use of macrolide antibiotics in patients with cystic fibrosis. Curr Opin Pulm Med 2004; 10(6): 515-523.
28. Pirzada OM, McGaw J, Taylor CJ, Everard ML. Improved lung function and body mass index associated with long-term use of macrolide antibiotics. J Cyst Fibrosis 2003; 2 (2): 69-71.
29. Mtairag EM, Abdelghaffar H, Douhet C, Labro MT. Role of extracellular calcium in in vitro uptake and intraphagocytic location of macrolides. Antimicrob Agents Chemother 1995; 39: 1676-1682.
30. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83(9): 2451-2458.
31. Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res 1994; 54(17): 4676-4679.
32. Yoshimura K, Nakamura H, Trapnell BC, et al. Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin. Nucleic Acids Res 1991; 19(19): 5417-5423.
33. Graff I, Schram-Doumont A, Szpirer C. Defective protein kinase C-mediated actions in cystic fibrosis neutrophils. Cell Signal 1991; 3(3): 259-266.
34. Hudson VM. New insights into the pathogenesis of cystic fibrosis: pivotal role of glutathione system dysfunction and implications for therapy. Treat Respir Med 2004; 3: 353-363.
35. Dormer RL, Harris CM, Clark Z, et al. Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005; 60: 55-59.
36. Kerem E. Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Curr Opin Pulm Med 2004; 10: 547-552.
37. Labro MT. Macrolide antibiotics: current and future uses. Exp Opin Pharmacother 2004; 5: 541-550.
38. Carr RR, Nahata MC. Azithromycin for improving pulmonary function in cystic fibrosis. Ann Pharmacother 2004; 38(9): 1520-1524.
39. De Wächter E, Malfroot A, De Schutter I, Vanbesien J, De Schepper J. Inhaled budesonide induced Cushing's syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. J Cyst Fibrosis 2003; 2(2): 72-75.
40. Prunier AL, Malbruny B, Laurans M, Brouard J, Duhamel JF, Leclercq R. High rate of macrolide resistance in Staphylococcus aureus strains in patients with cystic fibrosis reveals high proportions of hypermutator strains. J Infect Dis 2003; 187: 1709-1716.
41. Maeda K, Mikasa K, Konishi M, et al. Acute exacerbations due to Streptococcus pneumoniae in chronic lower respiratory infections during long-term macrolide therapy. Kansenshogaku Zasshi 2001; 75: 846-850.
42. Bauernfeind A, Jungwirth R, Eberlein E. Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens. Infection 1995; 23: 316-321.